Chronic lung disease of prematurity (CLD) is a frequent sequela of premature birth and oxygen toxicity is a major associated risk factor. Impaired alveolarization, scarring, and inflammation are hallmarks of CLD. Mast cell hyperplasia is a feature of CLD but the role of mast cells in its pathogenesis is unknown. We hypothesized that mast cell hyperplasia is a consequence of neonatal hyperoxia and contributes to CLD. Additionally, mast cell products may have diagnostic and prognostic value in preterm infants predisposed to CLD. To model CLD, neonatal wild-type and mast cell-deficient mice were placed in an O 2 chamber delivering hyperoxic gas mixture [inspired O2 fraction (FIO 2 ) of 0.8] (HO) for 2 wk and then returned to room air (RA) for an additional 3 wk. Age-matched controls were kept in RA (FI O 2 of 0.21). Lungs from HO mice had increased numbers of mast cells, alveolar simplification and enlargement, and increased lung compliance. Mast cell deficiency proved protective by preserving air space integrity and lung compliance. The mast cell mediators ␤-hexosaminidase (␤-hex), histamine, and elastase increased in the bronchoalveolar lavage fluid of HO wild-type mice. Tracheal aspirate fluids (TAs) from oxygenated and mechanically ventilated preterm infants were analyzed for mast cell products. In TAs from infants with confirmed cases of CLD, ␤-hex was elevated over time and correlated with FI O 2 . Mast cell exosomes were also present in the TAs. Collectively, these data show that mast cells play a significant role in hyperoxia-induced lung injury and their products could serve as potential biomarkers in evolving CLD.
IN THE UNITED STATES, chronic lung disease of prematurity (CLD), formerly referred to as bronchopulmonary dysplasia (BPD), is the most common complication of preterm birth, befalling 68% of infants born less than 29 wk gestation and weighing less than 1,500 g (54) . CLD is thought to result from inflammation-mediated injury that is modified by maternal and postnatal exposures, particularly supplemental oxygen. Despite a recent trend of decreasing mortality due to pulmonary causes among extremely premature infants (43) , preterm infants with CLD remain at high risk for respiratory morbidity and mortality (3) . Increased survival of premature infants is coupled to an increased incidence of childhood asthma that often persists into adulthood (3, 17, 22, 41, 65) . Premature birth and CLD also predispose for the development of chronic obstructive pulmonary disease (COPD) in later adulthood (16, 56, 65, 69, 70) . Insights into early factors that contribute to the pathogenesis of CLD are needed to develop better strategies for the prevention and treatment of at-risk premature newborns. Additionally, no solid biomarkers nor therapeutic interventions for amelioration of CLD have been identified (35) .
As inflammation is central to the development of CLD, inflammatory cells, including mast cells, are prominent in the lungs of preterm infants (31) . Genomewide transcriptional profiling recently confirmed that three of the five most highly induced genes in CLD are mast cell markers (7) . Accumulation of tryptase-positive mast cells in autopsy specimen obtained from infants with CLD was first described 20 years ago (31) . Mast cell hyperplasia has also been observed in baboons with BPD (55) . Despite evidence of their presence in CLD the pathophysiological contribution of mast cells is virtually unknown.
Over the past decade the multifactorial function of mast cells has been well documented (27) , including their pivotal role in local renin-angiotensin systems (12, 28, 33, 50) . Mast cell hyperplasia has been associated with numerous lung pathologies including fibrosis (46, 60) and pulmonary arterial hypertension coupled to hyperoxia (32) . Hyperoxia has been shown to cause mast cell hyperplasia in the lungs of young and adult rats (10) and airway inflammation and hyperresponsiveness in newborn rats (14, 47) . The purpose of the present study was to evaluate the role of mast cells associated with exposure to neonatal hyperoxia. Using a neonatal mouse model we tested the hypothesis that mast cells contribute to hyperoxia-induced damage of the newborn lung. We first determined whether the neonatal oxygen supplementation leads to mast cell hyperplasia and whether mast cells are responsible for the chronic disease-like pathology of alveolar simplification, a main feature of the COPD-like phenotype observed in adult CLD patients. Because of the dearth of biomarkers for CLD we also analyzed tracheal aspirate fluids (TAs) from a small cohort of mechanically ventilated and oxygenated preterm infants. It was hypothesized that mast cell products may be useful biomarkers for CLD owing to their association with BPD (7). Our results demonstrate that mast cells contribute to hyperoxia-induced impaired postnatal alveolarization in our mouse model of CLD and that mast cell products like ␤-hexosaminidase (␤-hex) and exosomes present in the TAs of oxygenated and ventilated preterm infants may serve as potential biomarkers in evolving CLD.
MATERIALS AND METHODS
Study design. This study was designed to determine the role of mast cells in hyperoxia-induced neonatal lung disease. Using neonatal mice on postnatal day 0, randomly chosen for the control and experimental groups, we determined whether exposure to hyperoxia led to an increase in mast cells and their transcripts concomitant to changes in lung structure and function. The neonatal hyperoxia protocol was then performed in mast cell-deficient mice (MCD). Each mouse experimental group included three to five mice per condition. PCR and immunoblotting were performed on a minimum of three different samples. The lung histological sections were evaluated by two investigators in a blinded fashion. The translational potential of these findings was explored by evaluating TAs from a cohort of 21 mechanically ventilated and oxygenated premature infants for mast cell mediators and exosomes. A total of 52 samples, some being sequential from the same patient, were analyzed. The exosomes isolated from the TAs of oxygenated and mechanically ventilated patients with a confirmed CLD diagnosis were compared with exosomes harvested from the supernatants of cultured human mastocytoma cells.
Approvals. Animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committee of Weill Cornell Medicine. TAs were obtained from parental consented mechanically ventilated and oxygenated patients in the neonatal intensive care unit (NICU) from December 2012 to January 2014. The protocol A: representative photomicrographs of lungs from 5-wk-old mice kept in room air (RA) or exposed to hyperoxia the first 2 wk of life followed by 3 wk in room air (HO). Mast cells (brown) and airway club cells (blue). Scale bar ϭ 50 m. B: graph of mast cells/mm 2 lung tissue from 2-and 5-wk-old RA and HO mice. Data are expressed as means Ϯ SE. ***P Ͻ 0.001 and ****P Ͻ 0.0001; HO vs. RA, by unpaired Student's t-test, n ϭ 5 mice/group. C-E: mouse lung homogenates (RA and HO) from the 5-wk time point were probed for the mast cell genes TPSAB1 (C), CPA3 (D), and TPSAB2 (E). Expression normalized to GAPDH. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001; HO vs. RA, by Student's t-test, n ϭ 3 mice/group. F: alveolar chord length Lm (m) measurements in fixed lung sections from 2-and 5-wk RA and HO mice. Data are expressed as means Ϯ SE. 2-wk: ***P Ͻ 0.001, HO vs. RA, n ϭ 4 mice/group; 5-wk: ****P Ͻ 0.0001, HO vs. RA, n ϭ 4 mice/group, NS ϭ not significant. G: analysis of static lung compliance in 5-wk RA and HO mice. Data are expressed as means Ϯ SE. ***P Ͻ 0.001, HO vs. RA, by unpaired Student's t-test, n ϭ 6 mice/group. H: analysis of static lung compliance in 20-wk RA and HO mice. Data are expressed as means Ϯ SE. *P Ͻ 0.05, HO vs. RA, n ϭ 6 mice/group. was approved by the Institutional Review Board of Weill Cornell Medicine.
Collection of tracheal aspirates. Preterm infants born at less than or equal to 32 wk gestational age who required mechanical ventilation and oxygen for respiratory distress syndrome at birth had TAs collected within the first 72 h, then weekly until extubation. CLD was defined as being dependent on supplemental oxygen for at least 28 days. For each sample, the mean 24-h inspired O 2 fraction (FIO 2 ) for the preceding day was calculated and an oxygenation index (FIO 2 ϫ mean airway pressure/arterial PO2; OI) was obtained if an arterial blood gas was available at the time of TA collection. Samples were collected at the time of routine suctioning of the endotracheal tube with 0.5 ml of normal saline instilled into the endotracheal tube. After two to three ventilator breaths the residue was obtained via endotracheal suctioning with a 5-or 6-French suction catheter. The aspirate was filtered through gauze to remove mucus and then centrifuged to obtain cell-free TAs. Samples were spun at 500 g for 10 min at 4°C. Cell pellets were resuspended in 100 l of PBS, then spun at 11,000 rpm for 20 min at 4°C, and the resultant supernatants were frozen at Ϫ80°C.
Mouse studies. For this study we utilized a well-defined murine model of CLD using neonatal mice chronically exposed to hyperoxia for 2 wk followed by normoxia for an additional 3 wk as we and others have previously described (8, 19, 20, 23, 40, 62, 67) . Timed pregnant mice were monitored hourly. Within hours of birth litters were pooled before being randomly redistributed to the newly delivered mothers. Experiments were begun on newborns at postnatal day 0. Half of the newborn pups were placed in a chamber designed to deliver variable oxygen concentrations (Biospherix) and set to 80% O 2 (HO), and the other half remained in room air (RA) as agematched controls. Mothers were rotated every 12 h to prevent death from acute O2 toxicity. Neonatal CD1 mice, also referred to as wild-type mice (Charles River), MCD mice (WBB6F1-W/Wv ), and their mast cell competent litter mates WBB6F1-ϩ / ϩ [congenic controls (CC)] (Jackson Laboratories) were exposed to either HO or RA for 2 wk and then kept in room air (FIO 2 of 0.21) an additional 3 wk for the 5-wk time point. Some CD1 mice (HO and RA) were also maintained 18 wk in room air for the 20-wk time point. Survival and weight were monitored daily. All mice (CD1, MCD, and CC) used in this study were healthy at birth and survived until euthanized. Unless specifically noted as CC or MCD, mouse experiments were performed with CD1 mice.
Bronchoalveolar lavage. Two-or 5-wk-old HO or RA mice (CD1) were euthanized with a lethal dose of pentobarbital (300 mg/kg), the trachea was cannulated with a 22-gauge catheter, and the lungs were washed twice with PBS (2 ϫ 0.5 ml). The bronchoalveolar lavage (BAL) fluid was pooled, filtered, and centrifuged, and the cell pellet was resuspended in buffer. Cells were spun onto glass slides by using a cytocentrifuge (Cytospin 3) and stained with Diff-Quick to count macrophages, neutrophils, and lymphocytes. Aliquots of cells from the BAL were stained with Trypan blue to determine viability and cells were counted by using a hemocytometer. Cell debris-free BAL fluid supernatants from 2-and 5-wk-old mice were used for analysis of ␤-hex, histamine, and elastase.
Lung mechanics. Pulmonary function tests were performed in 5-(CD1, MCD, and CC) and 20-wk-old mice (CD1) postneonatal HO or RA as previously described (15) . Briefly, mice were anesthetized with pentobarbital (100 mg/kg ip; American Pharmaceutical Partners), tracheostomized, and mechanically ventilated at a rate of 150 breaths/ min, a tidal volume of 10 ml/kg, and positive end-expiratory pressure Lungs from mice (CD1, MCD, and CC) not undergoing pulmonary function testing were fixed at a constant inflation pressure of 25 cmH 2O in 10% neutral buffered formalin followed by paraffin embedding. Slides with 7-m sections were deparaffinized, rehydrated, and washed in distilled water. Some sections were stained with hematoxylin and eosin (H&E) to visualize the structure of the lung. Other sections were stained with an antibody (CC10) (Santa Cruz Biotechnology) (1:50 dilution) to detect club cells, a cell type specific to the airways. Analysis on the alveolar space deliberately avoided airways and blood vessels. For each animal, five lung sections were analyzed and quantified as cells per square millimeter of lung tissue.
Mast cells were detected in fixed tissue using either the glycoprotein avidin, conjugated to the enzyme horseradish peroxidase (HRP) (Vector Laboratories) (6, 57, 60, 61) or toluidine blue, the classic metachromatic stain for mast cells (50) . Conjugated avidin is a well-defined histochemical method for identifying rodent and human mast cells, which express chondroitin sulfate E proteoglycans and heparin proteoglycans, respectively, in the secretory granules (52) , binding specifically to the proteoglycan granules (6, 57). We did not observe nonspecific staining of biotin or biotin-like molecules as previously reported (6, 61) . Deparaffinized sections were exposed to avidin-HRP 1:500. NovaRED (Vector Laboratories) was used as the chromogen substrate, according to the manufacturer's instructions.
Additional sections were immunoscreened for neutrophils, macrophages, B cells, and T cells. Following antigen retrieval with 10 mM sodium citrate buffer at 98°C for 20 min, rat anti-Ly-6G/-6C (1:50), rabbit anti-B220 (1:100), rabbit anti-CD3 (1:100), and rabbit antiMac-2 (1:50) primary antibodies (Abcam) were added followed by incubation with the appropriate HRP-conjugated secondary antibody (Jackson Laboratories).
Gömöri trichrome staining was performed with a dilution of Weigert's hematoxylin at 1:10 as previously described (60, 61) . Sections were stained with components from the trichrome kit and according to the manufacturer's protocol. After dehydration and clearing in xylene, the sections were mounted with coverslips in Vectamount (Vector Laboratories).
For all histological analyses tissue sections were viewed under transmitted light with a ϫ10 objective and an inverted epifluorescence microscope (Nikon Eclipse TE 2000-U) interfaced to a SPOT Insight 2 megapixel color camera (Diagnostic Instruments) and processed with Metamorph software (version 6.2; Universal Imaging). All histological analyses and cell number quantifications were performed by two investigators in a blinded fashion.
Lung air space analysis. We utilized the direct method for the accurate estimation of the mean linear intercept length (L m) (chord length) to assess the mean free distance in the alveoli as previously described (20, 24) . Entire tissue sections were imaged by capturing adjacent, nonoverlapping, fields. On average 30 -50 nonoverlapping 1-mm 2 fields were analyzed for each lung section and mean chord length of each alveolus (m) was measured.
␤-Hexosaminidase assay. ␤-Hex was assayed as previously described by using a modification of the method of Schwartz et al. (48): First, 20-l samples of BAL fluid from CD1 mice or TAs were placed into a 96-well plate. A total of 50 l of substrate solution (pnitrophenyl-N-acetyl-D-glucosamide; 1.3 mg/ml in 0.1 M citrate buffer, pH 4.5) was added to each well and incubated for 90 min at 37°C. The reaction was stopped by adding 150 l of 0.2 M glycine (pH 10.7). Optical density (OD) was read at 405 nm by using SoftMax Pro 4.8. Mean OD was calculated for each sample, run in duplicate. Sample variability was Ͻ0.5%. Mean OD values were converted to activity units by extrapolation to a standard curve generated for a range of p-nitrophenol concentrations. The concentration was multiplied by the volume and divided by the time used in the assay to get micromoles per hour, which is equivalent to 1 unit activity ␤-hex per Schwartz et al. (48) . The value was normalized using the amount of protein in each sample.
Histamine assay. Histamine content of the mouse BAL fluids (CD1) was assayed with an enzyme immunoassay kit (Immunotech, Marseille, France). Detection limit was 0.05 nM.
Neutrophil elastase assay. Neutrophil elastase was measured in mouse (CD1) BAL fluids with a mouse neutrophil elastase ELISA kit (TSZ ELISA, Waltham, MA), sensitivity of 1 ng/ml. Mast cell elastase is reported to be identical to neutrophil elastase (36) and will be referred throughout as elastase.
In vitro experiments. The human mastocytoma cell line, HMC-1, was kindly provided to us by J. H. Butterfield (Mayo Clinic, Rochester, MN). HMC-1 cells were cultured in Iscove medium (Hyclone Laboratories, Logan, UT) containing 10% FBS (Hyclone Laboratories), 1% penicillin/streptomycin (Mediatech, Manassas, VA), and 0.01% 1-thioglycerol (Sigma-Aldrich, St. Louis, MO). HMC-1 cells were grown to 1,000,000 cells/ml in complete medium (containing 10% FBS) and maintained at 37°C, 5% CO 2. Cells were spun down and resuspended in serum-free Iscove medium containing 1% penicillin/streptomycin and 0.01% 1-thioglycerol for 24 h. Cells were placed in a room air incubator or an incubator administering 70% oxygen.
Exosome isolation and characterization. Isolation of TA exosomes and HMC-1 supernatant exosomes was done as routinely performed in our laboratory (44) as follows. HMC-1 exosomes were collected from unstimulated HMC-1 cells maintained in room air or 70% oxygen for 24 h, 70% being the maximum level of oxygen administered by the incubator. Briefly, the TA samples or HMC-1 supernatants from 24-h cultures were pelleted by centrifugation at 500 g for 10 min. The supernatant was centrifuged at 12,000 g for 20 min. Exosomes were then harvested by centrifugation at 100,000 g for 70 min. The exosome pellet was resuspended in 20 ml of PBS and collected by ultracentrifugation at 100,000 g for 70 min (Beckman Ti70). Exosome size and particle number were analyzed by using the DS500 nanoparticle characterization system (NanoSight) equipped with a blue laser (405 nm).
Mass spectrometry analyses of exosomes from TAs (pooled from 4 confirmed CLD patients) and HMC-1 cells exposed to 70% O 2 or room air were performed at the Rockefeller University Proteomics Resource Center with 5-10 g of exosomal protein. Samples were denatured with 8 M urea, reduced with 10 mM DTT, and alkylated with 100 mM iodoacetamide. This was followed by proteolytic digestion with endoproteinase LysC (Wako Chemicals) overnight at room temperature and subsequent digestion with trypsin (Promega) for 5 h at 37°C. The digestion was quenched with formic acid and the resulting peptide mixtures were desalted with in-house-made C18 Empore (3M) STAGE tips (E1). Samples were dried and solubilized in the sample loading buffer containing 2% acetonitrile and 2% formic acid. Approximately 3-5 g of each sample was analyzed by reversed-phase nano-LC-MS/MS (Ultimate 3000 coupled to QExactive, Thermo Scientific). Following the loading on the C18 trap column (5 m beads, Thermo Scientific) at a flow rate of 3 l/min, peptides were separated by use of a 75-m inner diameter C18 column (3 m beads Nikkyo Technos) at a flow rate of 200 nl/min, with a gradient increasing from 5% buffer B (0.1% formic acid in acetonitrile)/95% buffer A (0.1% formic acid) to 40% buffer B/60% buffer A, over 140 min. All LC-MS/MS experiments were performed in data-dependent mode. Precursor mass spectra were recorded in a 300 -1400 m/z mass range at 70,000 resolution, and 17,500 resolution for fragment ions (lowest mass: m/z 100). Data were recorded in profile mode. Up to 20 precursors per cycle were selected for fragmentation and dynamic exclusion was set to 45 s. Normalized collision energy was set to 27. Data were extracted and searched against Uniprot complete Human or Mouse proteome databases (January 2013) concatenated with common contaminants (E2) by using Proteome Discoverer 1.4 (Thermo Scientific) and Mascot 2.4 (Matrix Science). All cysteines were considered alkylated with acetamide. NH 2-terminal glutamate to pyroglutamate conversion, oxidation of methionine, and protein NH2-terminal acetylation were allowed as variable modifications. Data were first searched by using fully tryptic constraints. Matched peptides were filtered by using a Percolator (E3) based 1% false discovery rate. Spectra not being matched at a false discovery rate of 1% or better were researched with allowance for semitryptic peptides. The average area of the three most abundant peptides for a matched protein (E4) was used to gauge protein amounts within and in between samples.
Electron microscopy. Purified exosomes from TAs were fixed in 2% paraformaldehyde (wt/vol) in 200 mM phosphate buffer (pH 7.4). Fixed exosomes were dropped onto a formvar-carbon-coated grid and left to dry at room temperature for 20 min. After washing in PBS, the exosomes were prepared in 1% glutaraldehyde for 5 min, washed in water and stained with saturated aqueous uranyl oxalate for 5 min. Samples were then embedded in 0.4% (wt/vol) uranyl acetate and 1.8% (wt/vol) methylcellulose and incubated on ice for 10 min. The excess liquid was then removed. The grid was dried at room temperature for 10 min and viewed at 20,000 and 50,000 magnification on an electron microscope (model 910, Carl Zeiss).
Western blotting. Aliquots of purified TA and HMC-1 exosomes were homogenized and the protein amounts determined by Lowry assay. Primary antibodies used were mouse monoclonal TSG 101 (Santa Cruz sc-7964) at 1:500 dilution, mouse monoclonal Alix (Cell Signaling, 2171) at 1:1,000 dilution, rabbit polyclonal CD63 (Santa Cruz, sc-15363) at 1:500 dilution, rabbit polyclonal chymase at a 1:2,500 dilution (Abcam, 186417), mouse monoclonal mast cell tryptase (Abcam, ab2378) at 1:3,000 dilution, rabbit polyclonal elastase (Abcam, ab68672) at 1:1,000 dilution, mouse monoclonal mast cell CPA3 (Abcam, ab72575) at 1:500 dilution, and mouse monoclonal ␤-actin (Cell Signaling, 3700) at 1:100,000 dilution. ␤-Actin was used as loading control.
Quantitative PCR. Lungs from 2-and 5-wk-old mice (CD1) were quickly excised, washed in cold PBS, cut in half, and then snap frozen in liquid nitrogen and stored at Ϫ80°C. To isolate the RNA, 15 mg of lung tissue was homogenized, then RNeasy (Qiagen, Valencia, CA) protocol was followed. RNA was quantified by use of a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA), and 0.76 g of RNA were reverse transcribed using the High Capacity RNAcDNA kit (Applied Biosystems, Foster City, CA). Quantitative PCR (qPCR) was performed at 1/10 dilution using fast SYBR Green Master Mix (Applied Biosystems) for mouse CPA3, TPSAB1, and TPSAB2 genes. GAPDH was used as the housekeeping gene and expression was constant. qPCR was done on a Step One real-time PCR system (Applied Biosystems).
The primers were as follows: CPA3 forward AATTGCTCCTGTC-CACTTTGAC, reverse TCACTAACTCGGAAATCCACAGT; TP-SAB1 forward GCCAATGACACCTACTGGATG, reverse GAGCT-GTACTCTGACCTTGTTG; TPSAB2 forward CTGGCTAGTCTG-GTGTACTCG, reverse CTGGCTAGTCTGGTGTACTCG; GAPDH forward AACAGCTCCCACTCTTC, reverse CCTGTTGCTG-TAGCCGTATT. All RNA samples had a 260/280 ratio of 1.8 or higher, indicating RNA purity of samples. TA exosomes. Exosome pellets were dissolved in RNeasy lysis buffer (Qiagen). RNA was isolated and quantified as above, and 45 ng of RNA were reverse transcribed by use of the High Capacity RNA-cDNA kit (Applied Biosystems). qPCR was performed at 1/4 dilution with fast SYBR Green Master Mix (Applied Biosystems) for human CPA3, TPSAB1, TPSAB2, and GAPDH genes able to detect as low as 1 copy of target DNA.
Human primers were as follows: CPA3 forward GGGTTTGATT-GCTACCACTCTT, reverse GCCAAGTCCTTTATGATGTCTGC; TPSAB1 forward GTGACGCAAAATACCACCTTGGC, reverse CATTCACCTTGCACACCAGGG; TPSAB2 forward CCGCGAC-CGATACTGGATG, reverse GATCTGGGCGGTGTAGAACT; GAPDH, forward CAACAGCACAGGAGAG, reverse CTACATG-GCAACTGTGAGGAG.
Statistics. Statistical comparisons were conducted by one-way ANOVA or unpaired two-tailed Student's t-test with GraphPad Prism 5.0 software (GraphPad, La Jolla, CA). A 95% confidence level was considered statistically significant. For the human samples, one-way ANOVA or unpaired two-tailed t-test was used to compare values between groups, whereas a paired t-test was used to compare week 1 to week 2 values within the same group. Values are expressed as means Ϯ SE. Regression analysis was used to estimate the degree of correlation between TA ␤-hex and OI as well as TA ␤-hex and FI O 2 .
RESULTS

Effect of neonatal hyperoxia on lung mast cells and their transcripts and lung structure and function.
We evaluated the effect of neonatal hyperoxia (HO) on the lung mast cell population. A preponderance of mast cells (stained brown) in the alveolar space, an anatomical compartment not typically associated with mast cells, was observed in HO mice. This was not seen in RA mice (Fig. 1A) . We quantified the number of avidin-positive mast cells present in the HO and RA lungs. HO significantly increased the number of mast cells in the lung compared with RA mice immediately following exposure to HO (2-wk time point) (P Ͻ 0.001), and after an additional 3 wk of breathing room air (5-wk time point) (P Ͻ 0.0001) (Fig.  1B) . This finding was verified with toluidine blue staining of HO and RA lung sections from the 2-wk time point (HO 85.1 Ϯ 8.5 mast cells/mm 2 vs. RA 4.0 Ϯ 2.8 mast cells/mm 2 ; P Ͻ 0.001).
To determine whether mast cell genes were upregulated in lung tissue we analyzed lung homogenates from the 2-and 5-wk time points for mRNA expression of the mast cellspecific markers TPSAB1, CPA3, and TPSAB2. Expression of all three mast cell genes was increased in the lungs from HO compared with RA mice at both time points. The data from the 5-wk time point is shown for TPSAB1 ( Fig. 1C ; P Ͻ 0.001), CPA3 ( Fig. 1D ; P Ͻ 0.05) and TPSAB2 ( Fig. 1E ; P Ͻ 0.01). These results are consistent with the observed increases in the lung mast cell population.
The area of the air spaces in lungs quantified by measuring chord length (L m ) was greater in lungs from HO compared with RA mice (Fig. 1F) at both 2 wk (P Ͻ 0.001) and 5 wk (P Ͻ 0.0001).
Consistent with the enlarged air space, static lung compliance was increased in HO mice compared with RA at the 5-( Fig. 1G ; P Ͻ 0.001) and 20-wk ( Fig. 1H ; P Ͻ 0.05) time points, indicating a sustained change in lung function. We did not detect a change in lung tissue resistance R or airway resistance Rn either at the 5-or 20-wk time points (not shown). Fixed lung sections from HO and RA mice from the 5-and 20-wk time points were screened for fibrosis. Fibrosis was not detectable in any samples (not shown). Similar results describing an attenuated phenotype of CLD with no changes in airway resistance have been reported by others using similar mouse models (62, 66) . Collectively these data show that neonatal hyperoxia leads to an increase in lung mast cells and a persistent and impaired alveolar phenotype, the latter leading to increases in lung compliance.
Effect of mast cell deficiency on lung function and structure in neonatal hyperoxia. To directly determine the role of mast cells in the lung pathology associated with neonatal hyperoxia, experiments were performed in 5-wk-old MCD and CC mice. HO did not lead to alveolar enlargement as in the CC mouse lungs (Fig. 2A) . In RA conditions, the alveolar air space, as determined by chord length, was not significantly different between the 5-wk MCD and CC mice (Fig. 2B) . Exposure to HO increased L m in the CC group (P Ͻ 0.0001) but not in the MCD mice. In accordance, lung compliance only increased in the CC group exposed to hyperoxia (P Ͻ 0.05) and not in the MCD mice exposed to hyperoxia (Fig. 2C) . These results describe a connection between mast cells and the structural and functional changes in the lung associated with neonatal hyperoxia.
Analysis of mouse BAL fluid for mast cell markers. To establish the importance of mast cell mediators in the neonatal hyperoxia-induced lung disease phenotype we evaluated mouse BAL fluids for mast cell mediators. HO increased BAL levels of ␤-hex ( Fig. 3A ; P Ͻ 0.01), an index of mast cell degranulation; histamine ( Fig. 3B ; P Ͻ 0.0001); and elastase ( Fig. 3C ; P Ͼ 0.0001). BAL differential cell counts showed that neonatal hyperoxia did not alter the overall number of inflammatory cells in the BAL at the 2- (Fig. 3D) or 5-wk time points (Fig. 3E) .
Analysis of fixed lung sections for inflammatory and immune cells.
To further analyze the immune and inflammatory response to HO, lung sections from CD1, MCD, and CC mice were screened for macrophages, neutrophils, and lymphocytes. Number and distribution of neutrophil, macrophage, and lymphocyte (T cells and B cells) populations were not affected by HO in CD1 mice at the 2-and 5-wk time points (Fig. 4) and in MCD and CC mice (Fig. 5 and Table 1 ). These data suggest that mast cells are the predominant pulmonary immune cell type that is increased at the 2-and 5-wk time points after exposure to neonatal hyperoxia. 
Analysis of tracheal aspirate fluids of preterm infants for the mast cell mediator ␤-hex.
The translational potential of the mouse findings was explored by evaluating TAs from a small cohort of 21 mechanically ventilated and oxygenated premature infants for mast cell mediators and exosomes. Table 2 includes the demographics for these 21 patients who contributed a total of 52 samples by weekly sampling until the time of extubation. The mean gestational age was 27.8 Ϯ 0.5 wk and mean birth weight was 1,015 Ϯ 93 g. Ten infants developed CLD, defined as dependence on supplemental oxygen for 28 days or more. Chorioamnionitis was present in three subjects. Tracheitis (as determined by TA culture) was not present in any infant at the time of collection. One infant died in the first month of life (Ͻ28 days) so CLD could not be determined (Table 2 , patient 16).
No significant difference in the TA ␤-hex activity levels was found at week 1 (initial sample) between the infants who developed CLD (red dots) (n ϭ 10) vs. those who did not develop CLD (blue dots) (n ϭ 10) (1.32 Ϯ 0.29 vs. 1.48 Ϯ 0.36) (Fig. 6A) . In the infants who were intubated Ͻ21 days and who developed CLD (with 2 sequential samples, n ϭ 4), there was no significant difference between week 1 and week 2 TA ␤-hex activity (1.12 Ϯ 0.56 vs. 2.06 Ϯ 0.92) (Fig. 6A) . In contrast, in the infants who developed CLD and who required prolonged intubation Ն21 days, TA ␤-hex activity increased in week 2 in each patient and this increase between week 1 and week 2 was significant [mean of groups 1.41 Ϯ 0.35 (n ϭ 7 with 5 sequential samples) vs. 5.12 Ϯ 1.27 (n ϭ 5), P Ͻ 0.01], as was the difference between week 1 TA ␤-hex values for all patients and week 2 values in CLD patients intubated Ն21 days (1.44 Ϯ 0.22 vs. 5.12 Ϯ 1.27, P Ͻ 0.0001) (Fig. 6A) . TA ␤-hex activity levels were not influenced by birth weight (Fig. 6B) or gestational age (Fig. 6C) .
Analysis of moderate correlations of ␤-hex activity levels with the OI were seen in the infants who had blood gas analysis performed (r 2 ϭ 0.28; Fig. 6D ) and with FI O 2 at the day of tracheal aspirate collection in all infants (r 2 ϭ 0.17; Fig. 6E , respectively). Both r values were significant relative to deviation from zero (P Ͻ 0.01, Fig. 6, D and E) . This suggests that ␤-hex activity levels were at least partially affected by the supplemental oxygen concentration.
Analysis of tracheal aspirates of preterm infants for mast cell exosomes. Mast cells are known to shed exosomal vesicles ranging in size from 30 to 100 nm when degranulating (25, 30) . To determine the diagnostic/prognostic potential of mast cell exosomes in lung secretions of preterm infants we examined the TAs for exosomes. Exosomes, as identified by their typical donut-shaped pattern, were seen by electron microscopy in pooled TAs from four infants with CLD (Fig. 7A) .
Although there are proteins that are characteristic of exosomes (e.g., tetraspanins, cytoskeletal proteins, and chaperones), exosome content varies depending on their source (11) . To determine whether mast cells contribute to the TA exosome population found in the TAs of infants with CLD, we analyzed purified exosomes from a pooled TA sample of four infants with CLD and supernatants of HMC-1 cells exposed to high oxygen by mass spectrometry. We found 133 proteins common to both the TAs and HMC-1 exosomes (Table 3 ) with 19 of these (italic font) being known proteins that are characteristic of exosomes (34) . Additionally, 82 of the 133 common proteins (bold font, Table 3 ) are known mast cell proteins.
We validated the proteomic results by Western blot analysis for the exosomal markers Alix (PDCD6IP), TSG-101, and CD63 identified by the mass spectrometry analysis. All three exosomal proteins were present in both TA and HMC-1 exosomes (Fig. 7B) . To determine whether we could detect exosomes with a mast cell signature in the TAs from the infants with CDL we screened them for the mast cell-specific transcripts CPA3 and TPSAB1. Both transcripts were present in the exosomes but their relative abundance varied among the four patient samples (Fig. 7C) .
Serine proteases and carboxypeptidase in mast cell exosomes. Exosomes are known to contain mRNA, miRNA, DNA, and protein from the host cells, which can be transferred to recipient cells (71) . The release of mast cell proteases like chymase and tryptase have been linked to tissue destruction in the lung (38) and heart (53, 73) . We sought to determine whether mast cell proteases are present in exosomes. Exosomes and lysates from HMC-1 cells were probed by Western blot for chymase, tryptase, elastase, and carboxypeptidase A3. All four proteases were present in the mast cell exosomes (Fig. 7D) . 
DISCUSSION
CLD is thought to result from inflammation-mediated injury and altered development of the premature lung that is modified by maternal and postnatal exposures (63) . In the present study we focus on the untoward effect of oxygen supplementation on CLD. Accumulating evidence indicates that mast cells play a role in CLD. Recently, transcript profiling of human CLD lung tissue obtained by autopsy identified that three of the five most highly upregulated genes in the CLD lungs were the mast cell-specific markers CPA3, TPSAB1, and TPSAB2 (7). Upregulation of these genes was also seen in FGFR3/4 knockout mice, a mouse model with features of CLD (51) . The human CLD lungs showed accumulation of chymase-expressing tissue mast cells (7) , also observed in severe asthma (2) and COPD (1). Despite evidence for important and medically relevant roles for mast cells in CLD, the pathophysiological contribution of mast cells in CLD is virtually unknown. Here, in a mouse neonatal hyperoxia model similar to protracted chronic lung disease of prematurity, we show that mast cells contribute to the CLD phenotype. Furthermore, we demonstrate that mast cell mediators and exosomes may represent disease-associated biomarkers for CLD.
In the neonatal hyperoxia mouse model we show mast cell hyperplasia, enlargement of the alveolar air space, and increased lung compliance. We also found upregulation of the mast cell-specific markers CPA3, TPSAB1, and TPSAB2 in lung homogenates of the HO mice. In the present study the contribution of mast cells to the CLD phenotype was verified with the MCD mice. Exposure to neonatal high oxygen did not lead to alveolar enlargement or increased lung compliance in MCD compared with CC and CD1 mice. We showed, by measuring chord length, that the alveolar air space of MCD mice (WBB6F1-W/Wv ) breathing room air is comparable to that of CC and CD1 mice. This is in contrast to that reported in a different strain of mast cell-deficient mice (Kit W-sh /Kit W-sh ). These mice develop spontaneous air space enlargement (29) . The genetic makeup of these different strains may account for this. The MCD mice used in our study have a mutated allele with a point mutation (threonine to methionine substitution position 660) in the kinase domain of the c-kit gene (4, 39) . The mutation in the Kit W-sh /Kit W-sh mice does not affect the c-kit gene itself but represents an inversion of a 3-cM segment on chromosome 5 ϳ72 kbp upstream of the c-kit transcriptional start site (4). It is likely that this accounts for the differences in the lung phenotype between the Kit W-sh /Kit W-sh and WBB6F1-W/Wv mice. Our mouse data show that neutrophil, macrophage, and lymphocyte populations are not elevated at the 2-and 5-wk time points post-neonatal hyperoxia. Significant increases in immune and inflammatory cells in the lungs have been observed at earlier time points (postnatal days 3-7) with hyperoxic exposure (5), suggesting that immune cells can be cleared from the lungs over time. The elevated mast cell population we observe in the lungs at the 2-and 5-wk time points suggests that they play an important role in the neonatal hyperoxic phenotype. Additionally lung mast cells express elastase (36) and are a likely source of elastase in the mouse BAL fluids.
Notwithstanding that CLD has a complex and heterogenous pathology, the lack of standardization in the rodent models of this disease contributes to our lack of understanding in its pathogenesis (49) . For example, increased lung compliance has been reported in mice more than 1 year after short-term (4 days) exposure to neonatal hyperoxia (72) . We found that the increased lung compliance we measured at 5 wk persists at the 20-wk time point in mice exposed to hyperoxia the first 2 wk of life (Fig. 1, G and H) . Others, however, have shown that prolonged (28 days) exposure to neonatal hyperoxia leads to decreased lung compliance and fibrosis (67), a phenotype described as more closely resembling "old" BPD (5) . This conveys that a varying duration and degree of neonatal hyperoxic exposure, as well as prenatal exposure to maternal inflammation (62), influences CLD severity and phenotype (10) . Also, the high FI O 2 used in our model is rarely required in the clinical setting. Future studies need to address the effect of lower FI O 2 on mast cell hyperplasia and lung architecture.
Our findings complement the work of Bhattacharya et al. (7) and offer an explanation for the mechanistic role of mast cells in CLD. No predilection was observed for the location of the mast cells in the lungs from HO mice. The mechanism responsible for the mast cell hyperplasia in CLD is not known. It has been suggested that mast cell precursors originating from the bone marrow and stimulated by the hyperoxia migrate to the lung where they differentiate to mast cell or uncommitted mast cell progenitor cells residing in the lung transform to mast cells in hyperoxic conditions (10) . Further experiments are necessary to explore these possibilities.
Therapeutic interventions for the amelioration of CLD are sorely lacking. Two trials studied the effects of aerosolized cromolyn, a mast cell stabilizer that prevents degranulation, in prevention and treatment of evolving BPD (64, 68) . These studies demonstrated no improvement in mortality, days on mechanical ventilation, or incidence of BPD, arguing against targeting mast cells for mitigating CLD. However, they did not assess drug delivery in these studies, thus failing to provide evidence for effective drug deposition (59) . It is feasible that other means of silencing mast cells will be developed that may be therapeutic for ameliorating CLD. Our recent study in CD1 mice using the same CLD neonatal hyperoxia model demonstrates that pharmacologically stabilizing hypoxia inducible factor during exposure to neonatal hyperoxia preserves the alveoli (20) .
In our search to identify early biomarkers of CLD we screened the TAs from mechanically ventilated and oxygenated infants, for mast cell products. Although TAs are primarily composed of upper airway secretions, in a study comparing TAs and BAL fluids from CLD and non-CLD patients, there was a correlation in IL-8 levels (13). These authors concluded that TAs could serve equally well for evaluating the development of BPD (13) .
Although the clinical data from TAs are obtained on a relatively small cohort of premature infants, the increased ␤-hex activity by week 2 could be a potential marker for those patients who will experience a more severe respiratory course (CLD and intubation Ն21 days). Early intervention in the prevention and/or attenuation of CLD is not yet possible. Identification of biomarkers for CLD will greatly enhance efforts in this area. Our results in the mouse neonatal hyperoxia model as well as with TAs suggest that mast cell products may be viable candidates with prognostic and diagnostic value.
Exosomes have been isolated from BAL fluid of patients with sarcoid (45) and asthma (42, 58) , but mast cell-derived exosomes have not been previously reported in the lung or lung surface fluid. We demonstrate for the first time the presence of mast cell exosomes in the respiratory tract of preterm infants. Exosomes derived from mesenchymal stem cells have been shown to have a therapeutic effect in a similar murine hyperoxia CLD model (18) and hypoxia-induced pulmonary hypertension (26) . It has been suggested that mast cell-derived exosomes could alter the phenotype of cells in a paracrine or endocrine fashion (37) . Our data show that mast cells shed protease-rich exosomes that could contribute to tissue remodeling and destruction associated with CLD. Our findings open the door for future studies on mast cell exosomes as a novel means of transferring mast cell secretory granule compounds to neighboring cells.
Establishing the mechanisms responsible for damage in the developing lung will provide valuable insights for advancing new and effective therapies in the treatment of CLD and possibly the development of emphysema and COPD later in life. Our mouse studies show that exposure to neonatal hyperoxia causes sustained damage to the perinatal lung. The enlarged alveolar space observed in response to neonatal hyperoxia has long-term consequences (16, 65) . A greater understanding of the changes evoked by oxidative stress and inflammation in the developing lung should help us better understand the pathogenesis of adult lung disease like emphysema and COPD (9) .
